Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in dahl rats with end-stage heart failure

International Heart Journal

Volumn 54, Issue 2, 2013, Pages 98-106

  Ishikawa, Mayuko ^a   Kobayashi, Naohiko ^a   Sugiyama, Fumihiro ^a   Onoda, Sho ^a   Ishimitsu, Toshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Inflammation; Nephrosclerosis; Oxidative stress

Indexed keywords

DESMIN; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEPHRIN; PODOCIN; PROTEIN P22 PHOX; PROTEIN P47 PHOX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RHO KINASE; TOLVAPTAN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL DAMAGE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HEART FAILURE; HIGH SODIUM INTAKE; INFLAMMATION; KIDNEY CORTEX; KIDNEY DYSFUNCTION; LONG TERM CARE; MALE; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BENZAZEPINES; CHEMOKINE CCL2; CHEMOKINE CCL5; DRUG EVALUATION, PRECLINICAL; EPITHELIAL-MESENCHYMAL TRANSITION; HEART FAILURE; KIDNEY CORTEX; MALE; MAP KINASE SIGNALING SYSTEM; NADPH OXIDASE; NEPHROSCLEROSIS; NF-KAPPA B; OXIDATIVE STRESS; PODOCYTES; RATS; RATS, INBRED DAHL; RECEPTORS, VASOPRESSIN; RHO-ASSOCIATED KINASES; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875880899     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.54.98     Document Type: Article

References (29)

1. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-9.
2. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-22. (Review)
3. Sebe A, Leivonen SK, Fintha A, et al. Transforming growth factorbeta-induced alpha-smooth muscle cell actin expression in renal proximal tubular cells is regulated by p38beta mitogen-activated protein kinase, extracellular signal-regulated protein kinase1,2 and the Smad signalling during epithelial-myofibroblast transdifferentiation. Nephrol Dial Transplant 2008; 23: 1537-45.
4. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGFbeta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-8.
5. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frøkiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647-63. (Review)
6. Morooka H, Iwanaga Y, Tamaki Y, et al. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail 2012; 5: 484-92.
7. Kobayashi N, Hara K, Tojo A, et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 2005; 45: 538-44.
8. Nishikimi T, Inaba-Iemura C, Ishimura K, et al. Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pept 2009; 154: 44-53.
9. Takeda Y, Nishikimi T, Akimoto K, Matsuoka H, Ishimitsu T. Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Hypertens Res 2010; 33: 965-73.
10. Koshikawa S, Nishikimi T, Inaba C, Akimoto K, Matsuoka H. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. J Hypertens 2008; 26: 1837-48.
11. Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J 2012; 76: 137-44.
12. Kobayashi N, Yoshida K, Nakano S, et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006; 47: 671-9.
13. Kobayashi N, Takeshima H, Fukushima H, et al. Cardioprotective effects of pitavastatin on cardiac performance and remodeling in failing rat hearts. Am J Hypertens 2009; 22: 176-82.
14. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-34 (Review)
15. Nishiyama A, Kobori H, Konishi Y, et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 2010; 332: 1072-80.
16. Ihara G, Kiyomoto H, Kobori H, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. J Hypertens 2010; 28: 2289-98.
17. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L. Diabetesinduced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003; 18: 1755-63.
18. Okada T, Sakaguchi T, Hatamura I, et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin Exp Nephrol 2009; 13: 438-46.
19. Chabrashvili T, Tojo A, Onozato ML, et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002; 39: 269-74.
20. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007; 22: 1314-22.
21. Armstead WM. Vasopressin-induced protein kinase C-dependent superoxide generation contributes to ATP-sensitive potassium channel but not calcium-sensitive potassium channel function impairment after brain injury. Stroke 2001; 32: 1408-14.
22. Li L, Galligan JJ, Fink GD, Chen AF. Vasopressin induces vascular superoxide via endothelin-1 in mineralocorticoid hypertension. Hypertension 2003; 41: 663-8.
23. Bauer J, Parekh N. Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat. Kidney Int 2003; 63: 2178-86.
24. Shimogai M, Ogawa K, Tokinaga Y, Yamazaki A, Hatano Y. The cellular mechanisms underlying the inhibitory effects of isoflurane and sevoflurane on arginine vasopressin-induced vasoconstriction. J Anesth 2010; 24: 893-900.
25. Song J, Martin DS. Rho kinase contributes to androgen amplification of renal vasoconstrictor responses in the spontaneously hypertensive rat. J Cardiovasc Pharmacol 2006; 48: 103-9.
26. Satoh S, Ikegaki I, Toshima Y, Watanabe A, Asano T, Shimokawa H. Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats. Life Sci 2002; 72: 103-12.
27. Nishikimi T, Akimoto K, Wang X, et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22: 1787-96.
28. Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16: 846-51.
29. Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP. Tolvaptan inhibits ERK-dependent cell proliferation, Cl-secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 2011; 301: F1005-13.